|
Synonyms: COT-143 | INFEX702
Compound class:
Antibody
Comment: RESP-X is a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa. It is being developed as an anti-virulence therapy for P. aeruginosa infections in patients with non-cystic fibrosis bronchiectasis.
|
| No information available. |
Summary of Clinical Use ![]() |
| A phase 1 study has been registered with the UK's Clinical Study Registry (ID ISRCTN17978477) to evaluate the safety and efficacy of RESP-X in healthy subjects and non-cystic fibrosis bronchiectasis patients colonized with P. aeruginosa [1]. In addition, RESP-X (results presented at the American Thoracic Society (ATS) 2026 International Conference [2]). |